EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma

BackgroundThe epidermal growth factor receptor (EGFR) is a primary target of molecular targeted therapy for lung adenocarcinoma (LUAD). The mechanisms that lead to epigenetic abnormalities of EGFR in LUAD are still unclear. The purpose of our study was to evaluate the abnormal methylation of EGFR Cp...

Full description

Bibliographic Details
Main Authors:	Zhanyu Xu, Fanglu Qin, Liqiang Yuan, Jiangbo Wei, Yu Sun, Junqi Qin, Kun Deng, Tiaozhan Zheng, Shikang Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Oncology
Subjects:	lung adenocarcinoma EGFR DNA methylation tumor biomarkers tumor-infiltrating
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.691915/full

Similar Items

Construction of 11 metabolic-related lncRNAs to predict the prognosis in lung adenocarcinoma
by: Wei Jiang, et al.
Published: (2023-12-01)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
by: Yingying Pan, et al.
Published: (2019-04-01)

Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma
by: Zhan-yu Xu, et al.
Published: (2020-07-01)

Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR‐mutated lung adenocarcinoma
by: Kei Kunimasa, et al.
Published: (2023-08-01)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
by: Fangqiu Fu, et al.
Published: (2021-04-01)

AGT May Serve as a Prognostic Biomarker and Correlated with Immune Infiltration in Gastric Cancer
by: Wu F, et al.
Published: (2022-02-01)

Analysis of immune status in gastric adenocarcinoma with different infiltrating patterns and origin sites
by: Nana Zhang, et al.
Published: (2022-08-01)

Tumor-infiltrating platelets promote the growth of lung adenocarcinoma
by: Xiaohui Li, et al.
Published: (2024-01-01)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
by: Zhulin Wang, et al.
Published: (2024-03-01)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
by: In Ae Kim, et al.
Published: (2018-07-01)

TAGAP expression influences CD4+ T cell differentiation, immune infiltration, and cytotoxicity in LUAD through the STAT pathway: implications for immunotherapy
by: Zhanyu Xu, et al.
Published: (2023-09-01)

Circulating <i>EGFR</i> Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
by: Shih-Hong Li, et al.
Published: (2022-09-01)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
by: Yangchun Gu, et al.
Published: (2021-12-01)

Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs
by: Ying‐Yuan Chen, et al.
Published: (2021-10-01)

Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma
by: Ping Zhang, et al.
Published: (2019-12-01)

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
by: Fei Zhou, et al.
Published: (2018-10-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
by: Wensheng Zhou, et al.
Published: (2022-03-01)

Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma
by: Xiaowei Qiu, et al.
Published: (2019-02-01)

CXCL10 is a Tumor Microenvironment and Immune Infiltration Related Prognostic Biomarker in Pancreatic Adenocarcinoma
by: Huimin Huang, et al.
Published: (2021-02-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
by: Yanxin Chen, et al.
Published: (2019-08-01)

STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway
by: Hui Xu, et al.
Published: (2021-06-01)

Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
by: Shafik Hanan Ezzat, et al.
Published: (2015-06-01)

The Study on Gene Amplification of EGFR in Bronchioloalveolar Carcinoma and Conventional Adenocarcinoma of the Lung
by: Xin SONG, et al.
Published: (2009-08-01)

Relationship between EGFR Mutations and Pathological Classification and  Specimen of Lung Adenocarcinoma
by: Lifei KANG, et al.
Published: (2017-06-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma
by: Guojin Zhang, et al.
Published: (2021-01-01)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
by: Zhang Y, et al.
Published: (2021-04-01)

Correlation between Immune Microenvironment Features and EGFR Mutation Status  in Lung Adenocarcinoma
by: Hongyu ZHU, et al.
Published: (2023-03-01)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Jiang-Yong Yu, et al.
Published: (2016-03-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Lijing Jiao, et al.
Published: (2019-07-01)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
by: Zheng H, et al.
Published: (2019-07-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs
by: Jiang S, et al.
Published: (2021-02-01)

Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures
by: Chen Huo, et al.
Published: (2021-07-01)

Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
by: Camila Robles-Oteiza, et al.
Published: (2021-11-01)